DRP™ for Oncology Ventures lead product LiPlaCis® registered for CE-marking in EU
Hoersholm, Denmark, January 9th, 2017 – Oncology Venture Sweden AB (OV.ST) today announced that CE-marking for the in vitro diagnostic medical device (IVD); the Drug Response Predictor – DRP™ – has been technically validated and registered for the lead drug candidate LiPlaCis®. A CE-marking shows that conformity assessment has been carried out and a technical file has been established by Medical Prognosis Institute A/S from whom OV has in-licensed the DRP™. The LiPlaCis DRP™ is key in the selection of high likely responding patients and pivotal in OV’s clinical breast cancer trial in